Correction to: Diabetes Ther (2021) 12:1359–1378 10.1007/s13300-021-01042-w
In the original article, ADR data from STELLA-ELDER are provided for Table 3 incorrectly which is originally for Table 2.
RESULTS
Safety
Original
ADR data from STELLA-ELDER are provided in Table 3 for comparison [9].
Corrected
ADR data from STELLA-ELDER are provided in Table 2 for comparison [9].
In the original article, Table S1 was published with some errors. The correct Table S1 is given below.
Original
| < 65 years | 65– < 75 years | ≥ 75 years | P-valuea | |
|---|---|---|---|---|
| All, n | 7894 | 2405 | 752 | |
| Sex, n (%) | ||||
| Male | 5023 (63.6) | 1305 (54.3) | 385 (51.2) | (1) < 0.001 |
| Female | 2871 (36.4) | 1100 (45.7) | 367 (48.8) | |
| Age, years | ||||
| Mean ± SD | 51.2 ± 9.0 | 68.7 ± 2.9 | 79.4 ± 3.9 | |
| Median (range) | 52.0 (14–64) | 68.0 (65–74) | 78.0 (75–95) | |
| Body weight, kg, mean ± SD (n) | 81.92 ± 17.35 (6015) | 68.74 ± 11.89 (1693) | 63.27 ± 11.46 (464) | (2) < 0.001 |
| BMI, kg/m2 | ||||
| Mean ± SD (n) | 29.90 ± 5.44 (5548) | 26.95 ± 4.06 (1536) | 26.02 ± 4.03 (408) | (2) < 0.001 |
| < 25.0, n (%) | 883 (11.2) | 515 (21.4) | 175 (23.3) | (1) < 0.001 |
| ≥ 25.0, n (%) | 4665 (59.1) | 1021 (42.5) | 233 (31.0) | |
| Unknown | 2346 (29.7) | 869 (36.1) | 344 (45.7) | |
| Duration of diabetes, years | ||||
| Mean ± SD (n) | 7.22 ± 5.74 (5417) | 9.80 ± 7.34 (1449) | 11.51 ± 9.17 (382) | (2) < 0.001 |
| < 5, n (%) | 2124 (26.9) | 382 (15.9) | 87 (11.6) | (1) < 0.001 |
| ≥ 5, n (%) | 3293 (41.7) | 1067 (44.4) | 295 (39.2) | |
| Unknown, n (%) | 2477 (31.4) | 956 (39.8) | 370 (49.2) | |
| Complications, n (%) | ||||
| Yes | 6603 (83.6) | 279 (11.6) | 88 (11.7) | (1) < 0.001 |
| No | 1232 (15.6) | 2107 (87.6) | 655 (87.1) | |
| Unknown | 59 (0.7) | 19 (0.8) | 9 (1.2) | |
| eGFR, mean mL/min/1.73 m2 ± SD (n) | 85.56 ± 19.35 (4762) | 72.48 ± 17.23 (1504) | 63.85 ± 18.83 (431) | (2) < 0.001 |
| HbA1c, n (%) | ||||
| Mean ± SD (n)b | 8.17 ± 1.51 (6413) | 7.84 ± 1.25 (1806) | 7.56 ± 1.15 (507) | (2) < 0.001 |
| < 8% | 3958 (50.1) | 1404 (58.4) | 473 (62.9) | (1) < 0.001 |
| ≥ 8% | 3473 (44.0) | 803 (33.4) | 206 (27.4) | |
| Unknown | 463 (5.9) | 198 (8.2) | 73 (9.7) | |
| Initial dose of ipragliflozin, n (%) | ||||
| 25 mg | 879 (11.1) | 369 (15.3) | 172 (22.9) | –c |
| 50 mg | 6999 (88.7) | 2033 (84.5) | 580 (77.1) | |
| 100 mg | 13 (0.2) | 2 (0.1) | 0 | |
| Other | 3 (0.04) | 1 (0.04) | 0 | |
| Daily dose of ipragliflozin, mg, mean ± SD (n) | 48.34 ± 8.39 (7894) | 47.27 ± 9.62 (2405) | 44.99 ± 10.60 (752) | (2) < 0.001 |
| Dose changes during treatment, n (%) | ||||
| 25 mg to 25 mg | 602 (7.6) | 274 (11.4) | 145 (19.3) | –c |
| 25 mg to 50 mg | 242 (3.1) | 78 (3.2) | 24 (3.2) | |
| 50 mg to 50 mg | 6765 (85.7) | 1958 (81.4) | 556 (73.9) | |
| 50 mg to 100 mg | 121 (1.5) | 35 (1.5) | 6 (0.8) | |
| Other | 164 (2.1) | 60 (2.5) | 21 (2.8) |
BMI body mass index, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, SD standard deviation
aP values across subgroups assessed by (1) chi-squared test, or (2) one-way analysis of variance; no statistical comparison between groups was made for specific complications
bMean HbA1c values were from the effectiveness analysis set
cNo P value was calculated when at least one element of the contingency table was < 10
Corrected
| < 65 years | 65– < 75 years | ≥ 75 years | P-valuea | |
|---|---|---|---|---|
| All, n | 7894 | 2405 | 752 | |
| Sex, n (%) | ||||
| Male | 5023 (63.6) | 1305 (54.3) | 385 (51.2) | (1) < 0.001 |
| Female | 2871 (36.4) | 1100 (45.7) | 367 (48.8) | |
| Age, years | ||||
| Mean ± SD | 51.2 ± 9.0 | 68.7 ± 2.9 | 79.4 ± 3.9 | |
| Median (range) | 52.0 (14–64) | 68.0 (65–74) | 78.0 (75–95) | |
| Body weight, kg, mean ± SD (n) | 81.92 ± 17.35 (6015) | 68.74 ± 11.89 (1693) | 63.27 ± 11.46 (464) | (2) < 0.001 |
| BMI, kg/m2 | ||||
| Mean ± SD (n) | 29.90 ± 5.44 (5548) | 26.95 ± 4.06 (1536) | 26.02 ± 4.03 (408) | (2) < 0.001 |
| < 25.0, n (%) | 883 (11.2) | 515 (21.4) | 175 (23.3) | (1) < 0.001 |
| ≥ 25.0, n (%) | 4665 (59.1) | 1021 (42.5) | 233 (31.0) | |
| Unknown | 2346 (29.7) | 869 (36.1) | 344 (45.7) | |
| Duration of diabetes, years | ||||
| Mean ± SD (n) | 7.22 ± 5.74 (5417) | 9.80 ± 7.34 (1449) | 11.51 ± 9.17 (382) | (2) < 0.001 |
| < 5, n (%) | 2124 (26.9) | 382 (15.9) | 87 (11.6) | (1) < 0.001 |
| ≥ 5, n (%) | 3293 (41.7) | 1067 (44.4) | 295 (39.2) | |
| Unknown, n (%) | 2477 (31.4) | 956 (39.8) | 370 (49.2) | |
| Complications, n (%) | ||||
| Yes | 6603 (83.6) | 2107 (87.6) | 655 (87.1) | (1) < 0.001 |
| No | 1232 (15.6) | 279 (11.6) | 88 (11.7) | |
| Unknown | 59 (0.7) | 19 (0.8) | 9 (1.2) | |
| eGFR, mean mL/min/1.73 m2 ± SD (n) | 85.56 ± 19.35 (4762) | 72.48 ± 17.23 (1504) | 63.85 ± 18.83 (431) | (2) < 0.001 |
| HbA1c, n (%) | ||||
| Mean ± SD (n)b | 8.17 ± 1.51 (6413) | 7.84 ± 1.25 (1806) | 7.56 ± 1.15 (507) | (2) < 0.001 |
| < 8% | 3958 (50.1) | 1404 (58.4) | 473 (62.9) | (1) < 0.001 |
| ≥ 8% | 3473 (44.0) | 803 (33.4) | 206 (27.4) | |
| Unknown | 463 (5.9) | 198 (8.2) | 73 (9.7) | |
| Initial dose of ipragliflozin, n (%) | ||||
| 25 mg | 879 (11.1) | 369 (15.3) | 172 (22.9) | –c |
| 50 mg | 6999 (88.7) | 2033 (84.5) | 580 (77.1) | |
| 100 mg | 13 (0.2) | 2 (0.1) | 0 | |
| Other | 3 (0.04) | 1 (0.04) | 0 | |
| Daily dose of ipragliflozin, mg, mean ± SD (n) | 48.34 ± 8.39 (7894) | 47.27 ± 9.62 (2405) | 44.99 ± 10.60 (752) | (2) < 0.001 |
| Dose changes during treatment, n (%) | ||||
| 25 mg to 25 mg | 602 (7.6) | 274 (11.4) | 145 (19.3) | –c |
| 25 mg to 50 mg | 242 (3.1) | 78 (3.2) | 24 (3.2) | |
| 50 mg to 50 mg | 6765 (85.7) | 1958 (81.4) | 556 (73.9) | |
| 50 mg to 100 mg | 121 (1.5) | 35 (1.5) | 6 (0.8) | |
| Other | 164 (2.1) | 60 (2.5) | 21 (2.8) |
BMI body mass index, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, SD standard deviation
aP values across subgroups assessed by (1) chi-squared test, or (2) one-way analysis of variance; no statistical comparison between groups was made for specific complications
bMean HbA1c values were from the effectiveness analysis set
cNo P value was calculated when at least one element of the contingency table was < 10